ArticleScience (New York, N.Y.)2020
An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis.
Article in Science (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
170 citing papers in PubMed, 1 synthesis or guideline pooled it, 307 citations in OpenAlex.
- Integrative evidence construction for resveratrol treatment of nonalcoholic fatty liver disease: preclinical and clinical meta-analyses.Frontiers in pharmacology · 2023Pooled it
- Pharmacodynamic effects of direct AMP kinase activation in humans with insulin resistance and non-alcoholic fatty liver disease: A phase 1b study.Cell reports. Medicine · 2021Trial
- Molecular mechanisms and pathogenesis of MASH.Nature · 2026Review
- Review
- Hepatocyte estrogen-related receptor α modulates a gluconeogenic-epigenetic crosstalk counteracting MASLD/MASH progression.Experimental & molecular medicine · 2026Article
- Caspase-6 Controls Lipid and Energy Metabolism in Diet-Induced Obesity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Methionine and choline deficiency rewires transcriptional programs to recapitulate molecular features of human MASH.Journal of lipid research · 2026Article
- Integration proteomics analysis to identify AMPK as key target pathways of TCM formula for high fat diet induced obesity in mice.Journal of traditional and complementary medicine · 2026Article
- TANK-binding kinase 1 protects against MASH progression via mitochondrial quality control.Experimental & molecular medicine · 2026Article
- The Intricate Role of Caspase-6 and Death Receptor-6 in Neurodegenerative Diseases.Cell biochemistry and biophysics · 2026Review
- AMPK maintains the activation of hepatic stellate cells through mitophagy-induced metabolic reprogramming.Journal of molecular cell biology · 2026Article
- Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk.Lipids in health and disease · 2026Review
- Ghardaqenoids A-F: Six New Diterpenoids from the South China Sea Soft CoralMarine drugs · 2026Article
- Serum biomarker screening and metabolic profiling analysis of nonalcoholic fatty liver disease patients using untargeted metabolomics and machine learning techniques.Frontiers in molecular biosciences · 2026Article
- AMPK at the interface of nutrient sensing, metabolic flux and energy homeostasis.Nature metabolism · 2026Review
- Nicorandil attenuates thioacetamide induced liver fibrosis via AMPK, SIRT1 and HIF1α mediated cellular energy homeostasis.Scientific reports · 2025Article
- AMP-activated protein kinase-Caspase 6 axis regulation alleviates the combined apoptotic damage caused by deoxynivalenol and fumonisin B1 in mammary glands.NPJ science of food · 2025Article
- Akkermansia muciniphila alleviates metabolic disorders through gut microbiota-mediated tryptophan regulation.AMB Express · 2025Article
- Tank-Binding Kinase 1 protects against MASH progression via mitochondrial quality control.Research square · 2025Article
- Liver, ageing and disease.Nature reviews. Gastroenterology & hepatology · 2025Review
110 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 1 institution in 1 country.
Funding
Abstract
Liver cell death has an essential role in nonalcoholic steatohepatitis (NASH). The activity of the energy sensor adenosine monophosphate (AMP)-activated protein kinase (AMPK) is repressed in NASH. Liver-specific AMPK knockout aggravated liver damage in mouse NASH models. AMPK phosphorylated proapoptotic caspase-6 protein to inhibit its activation, keeping hepatocyte apoptosis in check. Suppression of AMPK activity relieved this inhibition, rendering caspase-6 activated in human and mouse NASH. AMPK activation or caspase-6 inhibition, even after the onset of NASH, improved liver damage and fibrosis. Once phosphorylation was decreased, caspase-6 was activated by caspase-3 or -7. Active caspase-6 cleaved Bid to induce cytochrome c release, generating a feedforward loop that leads to hepatocyte death. Thus, the AMPK-caspase-6 axis regulates liver damage in NASH, implicating AMPK and caspase-6 as therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.